Cargando…

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure

Detalles Bibliográficos
Autores principales:	Verbrugge, Frederik H., Borlaug, Barry A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670505/ https://www.ncbi.nlm.nih.gov/pubmed/32552147 http://dx.doi.org/10.1161/JAHA.120.017292

Ejemplares similares

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
por: Dizaye, Kawa, et al.
Publicado: (2019)

Angiotensin Receptor‐Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension
por: Sharifi Kia, Danial, et al.
Publicado: (2020)

Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure
por: Kashiwagi, Yusuke, et al.
Publicado: (2023)

Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
por: Singh, Jagdeep SS, et al.
Publicado: (2015)

Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure
por: Sun, Yuxi, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper
por: Ntalianis, Argyrios, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
por: Cho, In-Jeong, et al.
Publicado: (2021)

Heart Failure Treatments Such As Angiotensin Receptor/Neprilysin Inhibitor Improve Heart Failure Status and Glucose Metabolism
por: Kashiwagi, Yusuke, et al.
Publicado: (2022)

Impact of angiotensin receptor–neprilysin inhibition on vascular function in heart failure with reduced ejection fraction: A pilot study
por: Nathaniel, Sangeetha, et al.
Publicado: (2022)

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
por: Choi, Hong-Mi, et al.
Publicado: (2020)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
por: Esser, Nathalie, et al.
Publicado: (2022)

Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure
por: Mukhopadhyay, Amrita, et al.
Publicado: (2022)

Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
por: Park, Su Yeong, et al.
Publicado: (2023)

Is there a place for angiotensin receptor-neprilysin inhibitors in the treatment of heart failure patients after heart transplantation?
por: Gulin, Dario, et al.
Publicado: (2019)

Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction
por: Grant, Andrew D.M., et al.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure
por: Ding, Kun, et al.
Publicado: (2022)

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series
por: Taghavi, Sepideh, et al.
Publicado: (2020)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

Increased concentrations of bioactive adrenomedullin subsequently to angiotensin‐receptor/neprilysin‐inhibitor treatment in chronic systolic heart failure
por: Arfsten, Henrike, et al.
Publicado: (2020)

Combined Angiotensin Receptor–Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure
por: Trivedi, Rishi K., et al.
Publicado: (2018)

Long‐term impact of angiotensin receptor‐neprilysin inhibitor based on short‐term treatment response in heart failure
por: Park, Hyuk Kyoon, et al.
Publicado: (2023)

Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure
por: Pfau, Daniel, et al.
Publicado: (2019)

Real-world Practical Experience of Angiotensin Receptor-neprilysin Inhibitor in Older Japanese Patients with Chronic Heart Failure
por: Komatsu, Toshinori, et al.
Publicado: (2023)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study
por: Wang, Xiaobo, et al.
Publicado: (2023)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
por: Ryazanov, A.S., et al.
Publicado: (2023)

Characterization of heart failure patients with reverse left ventricular remodelling post‐angiotensin receptor blockers/neprilysin inhibitors therapy
por: Maizels, Leonid, et al.
Publicado: (2022)

Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF
por: Chapman, Brittany, et al.
Publicado: (2022)

Chronic kidney disease, heart failure and neprilysin inhibition
por: Haynes, Richard, et al.
Publicado: (2020)

Relationship Between Hospital Characteristics and Early Adoption of Angiotensin‐Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure
por: Luo, Nancy, et al.
Publicado: (2019)

Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials
por: Bratsos, Sosipatros
Publicado: (2019)

The Impact of Angiotensin Receptor–Neprilysin Inhibitors on Arrhythmias in Patients with Heart Failure: A Systematic Review and Meta-analysis
por: Mujadzic, Hata, et al.
Publicado: (2022)

The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials
por: Chen, Yan, et al.
Publicado: (2022)

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
por: Tsai, Ming-Lung, et al.
Publicado: (2023)

Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists
por: Dalal, Jamshed, et al.
Publicado: (2023)

Design of the Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor Versus Placebo in Patients With Congenital Systemic Right Ventricle Heart Failure (PARACYS-RV) Trial
por: Chaix, Marie-A., et al.
Publicado: (2023)

Angiotensin Receptor-Neprilysin Inhibition for Doxorubicin-Mediated Cardiotoxicity: Time for a Paradigm Shift
por: Hahn, Virginia S., et al.
Publicado: (2020)

Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
por: Verbrugge, Frederik H, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cntoegv41sf28r2u0h8gt358e4